CEO'S REPORT

Our highly scalable business model is underpinned by defensive industry characteristics. With the infrastructure already in place and a clear, defined runway to keep growing, in Australia and internationally, we are confident the model will keep compounding value.

Vikesh Ramsunder
Managing Director & Chief Executive Officer

Dear Shareholders,

FY26 was a year of strong execution and continued momentum for Sigma. Since the merger in February 2025, our priorities have been clear: integrate the combined business with discipline, deliver sustainable growth, and strengthen the platform required to create long-term shareholder value.

The year demonstrated the complementary strengths of Sigma and Chemist Warehouse, with growth across domestic and international operations, improved operating leverage, and continued progress on integration and synergy delivery.

For FY26, Sigma delivered revenue of $10.4 billion from our Australian segment and $0.4 billion from our International segment. Normalised EBIT* increased 20.6% to $1,090.0 million, with the Australian segment contributing $1,034.2 million and the International segment $55.8 million.

To put these results in context, the Prospectus pre-merger disclosed FY24 pro-forma revenue of $6.7 billion and pro-forma EBIT of $605.5 million. We have come a long way in a short period of time.

These results reflect the resilience of the pharmacy sector, the strength of our integrated model, and disciplined execution against our four strategic pillars.

Domestic Growth Continues

Australia remains our core market and a substantial long-term growth opportunity. We continue to see scope to expand both our retail and wholesale businesses through disciplined network growth, stronger franchisee support and continued customer engagement.

Chemist Warehouse branded network sales# in Australia increased 15.9% to $10.2 billion, supported by like-for-like sales growth of 13.4%, a compelling value proposition and continued network expansion.

Growth was also supported by the structural uplift from GLP-1 medicines, which we see as enduring. With the potential future availability of solid tablet forms, which are expected to be more affordable, we continue to view GLP-1 medicines as a long-term opportunity for pharmacies, bringing with it an increasing demand across complementary health categories.

We added 24 new Chemist Warehouse branded stores in Australia this financial year, taking the network to 561 stores, while 18 franchisees refurbished existing sites to improve customer experience and support like-for-like sales growth.

We also made significant progress reinvigorating the Amcal and Discount Drug Stores brands, including the conversion of MyChemist franchise stores into Amcal and DDS franchises. This simplifies our portfolio and strengthens our ability to serve different customer segments and market locations.

International Expansion Accelerates

International growth remains one of Sigma's four key strategic pillars, and FY26 reinforced the scalability of the Chemist Warehouse model beyond Australia.

International retail network sales^ exceeded $1.6 billion, increasing 23.3% with like-for-like sales growth of 12.2%. This performance strengthens our confidence in the relevance of the Chemist Warehouse proposition across offshore markets.

New Zealand continued to perform well, with 14 stores opened during FY26, taking the network to 75 stores, with an ambition of more than 100 Chemist Warehouse stores in New Zealand. We also announced our approximately $40 million investment in a new 23,000 square metre distribution centre in Auckland to support future expansion. This is expected to commence operating in September 2026.

Ireland is also scaling well, with four new stores opened during FY26 and the distribution centre now fully operational. The store network in Ireland has tripled from 6 to 18 over the last three years, with the business now reaching profitability for the first time as we look to accelerate growth. In the UAE, the network remains at an early stage, with three stores at year end and encouraging customer response.

* Normalised for one-off merger, integration and other costs. FY25 comparison period is based on pro-forma assuming Sigma and Chemist Warehouse Group (CWG) were merged from 1 July 2024.
# Refer to pages 8 to 9 for a definition of Chemist Warehouse branded network sales.
^ Refer to pages 16 to 17 for a definition of International retail network sales.

In May 2026, we also announced our entry into the United Kingdom through a joint venture with GreenLight Healthcare. This is another important milestone in building a scalable international growth platform. We anticipate opening our first Chemist Warehouse store in the United Kingdom before the end of the 2026 calendar year.

Product Differentiation and Margin Expansion

Our own and exclusive label strategy continues to strengthen customer differentiation and margin expansion while maintaining the Chemist Warehouse position as a house of brands.

During FY26, we launched more than 470 new own and exclusive label products. Sales of own and exclusive label product grew 15% in FY26 to approach $1.0 billion, which is close to 10% of the Chemist Warehouse branded store network sales.

This strategy allows us to close category gaps, improve customer value, deepen supplier relationships and enhance margins across the network.

The Wagner Pharmaceuticals generics range of products remains an important growth pillar, and achieved 88% customer adoption rate on available product across the Chemist Warehouse network. Attention is set to turn to further longer term opportunities in both the domestic and international segments.

Supply Chain and Integration Progress

FY26 also highlighted the operating leverage and efficiency benefits available across the combined business.

From our distribution centres across Australia we made over 600k deliveries, distributing more than 579 million units, up 6.5%, while the distribution cost per unit decreased year on year. This demonstrates the scalability of our infrastructure and the benefits of combining retail and wholesale operations.

Pleasingly, in the most recent independent Advantage Group Survey of suppliers, Sigma has improved significantly to now be ranked the number one wholesaler in Australia.

Our integration program is on track. Importantly, this is not just about consolidation. We have mapped the change management required to deliver an SAP upgrade and integration of Sigma and the Chemist Warehouse Group onto existing IT infrastructure. We are also embedding AI capability across the business to support decision making.

Key priorities include supply chain consolidation, technology simplification, supplier rationalisations and leveraging franchisee support capability across the combined network.

Outlook

Our growth profile and momentum remain strong across Australia and our international expansion markets. Our strong balance sheet and operating cash flow provides flexibility to invest for future growth while maintaining our commitment to shareholder returns.

As a business, we are leaning more into the capabilities and opportunities that AI can deliver and how it can improve our own internal performance, decision making and efficiency. We are also continuously seeking to improve our cyber security posture to adapt to the evolving online and cyber challenges every business faces every day.

There is persistent macroeconomic uncertainty and challenges globally, contributing to cost-of-living pressures across our core Australian market. I remain confident in the resilience of the healthcare sector, the strength of our business model and customer value proposition, and our ability to grow our market share across the market.

I thank our team members, franchise partners, suppliers and shareholders for their continued support throughout another significant year for Sigma.

Vikesh Ramsunder
Managing Director
& Chief Executive Officer